AJR Am J Roentgenol
- MARGOLIS DJA, Chatterjee A, deSouza NM, Fedorov A, et al
Quantitative Prostate MRI, From the AJR Special Series on Quantitative Imaging.
AJR Am J Roentgenol. 2024 Oct 2. doi: 10.2214/AJR.24.31715.
BJU Int
- DAUNGSUPAWONG H, Wiwanitkit V
Comment on 'Socioeconomic disparities in prostate cancer screening: the impact of
the Area Deprivation Index on PSA screening frequency'.
BJU Int. 2025 Sep 4. doi: 10.1111/bju.16922.
- VLAMING M, Koole W, van Moorselaar RJA, Bleiker EMA, et al
Prevalence of germline pathogenic variants in 779 patients with metastatic
prostate cancer.
BJU Int. 2025 Sep 2. doi: 10.1111/bju.16916.
- BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
Reply to 'Comment on Bertini et al.: area deprivation and PSA screening
disparities' and 'Comment on socioeconomic disparities in prostate cancer
screening: the impact of the Area Deprivation Index on PSA screening frequency'.
BJU Int. 2025 Sep 4. doi: 10.1111/bju.16924.
- ROBERTS IA, Cumberbatch MG, Catto JWF
Renal, bladder and prostate cancer surgery outcomes with respect to team
familiarity.
BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
BMC Urol
- LUDECKE J, Mohr MN, Schneider TR, Voss JW, et al
Combined robot-assisted surgery of upper and lower genitourinary tract with
excellent early functional and oncological outcome - a case report of a
concomitant nerve-sparing radical prostatectomy, diverticulectomy and
ureterectomy.
BMC Urol. 2025;25:225.
- AGUILA-GIMENO O, Jareno-Vicens A, Recasens CT
Pelvic floor rehabilitation before radical prostatectomy: a systematic review.
BMC Urol. 2025;25:224.
Br J Cancer
- HUANG H, Benzonana LL, Zhao H, Watts HR, et al
Correction to: Prostate cancer cell malignancy via modulation of HIF-1alpha pathway
with isoflurane and propofol alone and in combination.
Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03175.
Cancer
- NGUYEN DD, Satkunasivam R, Aminoltejari K, Hird A, et al
Association of patient and physician characteristics with
androgen-deprivation-therapy intensification in patients with de novo
hormone-sensitive metastatic prostate cancer: A population-based study.
Cancer. 2025;131:e70070.
- NIERENGARTEN MB
Outcomes show a reduction in treatment failure associated with dose-escalated,
hypofractionated radiation therapy for localized prostate cancer.
Cancer. 2025;131:e70013.
- NIERENGARTEN MB
A persistent PSA level following radical prostatectomy for prostate cancer is
associated with a worse prognosis.
Cancer. 2025;131:e70012.
Cancer Res
- JIANG J, Liu S, Xu C, He L, et al
LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in
Prostate Cancer.
Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-0587.
- MURPHY KC, DeMarco KD, Zhou L, Peura J, et al
MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T
Cell and Immunotherapy Responses in Prostate Cancer.
Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-2532.
- LIU S, Hsu EC, Aslan M, Garcia-Marques F, et al
Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate
Cancer Metastasis.
Cancer Res. 2025 Sep 5. doi: 10.1158/0008-5472.CAN-24-4855.
Eur J Radiol
- AGHAKHANYAN G, Barucci A, Pascali MA, Assante M, et al
NAVIGATOR: A regional multimodal imaging biobank initiative powered by AI tools
for precision medicine in oncology.
Eur J Radiol. 2025;191:112327.
- CURIA B, Bortolotto C, Brizzi L, Santagostini S, et al
Impact on MRI technologist of a PI-QUAL v2 educational program on prostate MRI
image quality assessment.
Eur J Radiol. 2025;191:112280.
- NATALI T, Kurucz LM, Fusaglia M, Mertens LS, et al
Automatic prostate volume estimation in transabdominal ultrasound images.
Eur J Radiol. 2025;191:112274.
- BRENDER JR, Ota M, Nguyen N, Ford JW, et al
Predicting ADC map quality from T2-weighted MRI: A deep learning approach for
early quality assessment to assist point-of-care.
Eur J Radiol. 2025;191:112317.
Int J Urol
- KAWASE M
Editorial Comment Regarding "Shifts in Diagnostic Approaches for Prostate Cancer:
Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection".
Int J Urol. 2025 Sep 1. doi: 10.1111/iju.70218.
- MATSUYAMA N, Suzuki K, Tobe T, Ueki H, et al
Time to Oligoprogression From the Initiation of the Most Recent Systemic
Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for
Castration-Resistant Prostate Cancer.
Int J Urol. 2025 Sep 2. doi: 10.1111/iju.70217.
- SUZUKI K, Hirata J, Ueki H, Wakita N, et al
Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients
With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional
Analysis.
Int J Urol. 2025 Sep 3. doi: 10.1111/iju.70219.
J Magn Reson Imaging
- LIU BC, Ding XH, Xu HH, Bai X, et al
Preoperative Assessment of Extraprostatic Extension in Prostate Cancer Using an
Interpretable Tabular Prior-Data Fitted Network-Based Radiomics Model From MRI.
J Magn Reson Imaging. 2025 Sep 5. doi: 10.1002/jmri.70111.
J Urol
- CHEN DC, Alhamdani Z, Papa N, Shen E, et al
The Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is
Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane
Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
J Urol. 2025 Sep 5:101097JU0000000000004734. doi: 10.1097/JU.0000000000004734.
Lancet Oncol
- NIAZI T, Saad F, Tisseverasinghe S, Koul R, et al
Metastases-directed therapy in addition to standard systemic therapy in
oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a
multicentre, open-label, randomised, phase 2 trial.
Lancet Oncol. 2025;26:1158-1167.
Nat Rev Urol
- FEIJO M, Carvalho TMA, Fonseca LRS, Vaz CV, et al
Endocrine-disrupting chemicals as prostate carcinogens.
Nat Rev Urol. 2025;22:609-631.
Oncogene
- CIVENNI G, Sandrini G, Merulla J, Musumeci C, et al
Integrated control of cancer stemness by sigma(1) receptor in advanced prostate
cancer.
Oncogene. 2025 Sep 2. doi: 10.1038/s41388-025-03541.
- RAZA M, Rajan AR, Kennedy BB, Reznicek TE, et al
ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by
regulating glycolysis.
Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03559.
Pol J Radiol
- SARA HI, Aydin H, Hizli F
The use of ADC histogram analysis in the diagnosis and determination of
aggressiveness of peripheral zone prostate cancer.
Pol J Radiol. 2025;90:e374-e383.
Prostate
- YUKIHIRO K, Sekino Y, Kobayashi G, Hatayama T, et al
Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer
Treatment.
Prostate. 2025 Sep 1. doi: 10.1002/pros.70042.
- MARTINEZ OSORIO CA, Sopena Sutil R, Vilaseca Cabo A, Linares Espinos E, et al
Prostate-Specific Antigen Response at Six Months Predicts Progression in
Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.
Prostate. 2025 Sep 4. doi: 10.1002/pros.70040.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016